Bio News
GSK announced a restructuring plan to cut 3.75 trillion won ($2.5 billion) annually by 2029 to secure funding for late-stage R&D. The restructuring will incur a one-time cost of 4.8 trillion won ($3.2 billion), with the savings reinvested in late-stage pipelines, including antibody-drug conjugates (ADCs). GSK also plans to invest £400 million to establish a new research headquarters in Cambridge and accelerate the development of seven key assets.
Biobook Team
biobookmedia@biobook.co.krAsahi Kasei Wins FDA Approval for New Herpes Drug Hovlpri for Immunocompromised Adults
Mirum’s Livmarli succeeds in phase 3 trial, company seeks expanded indication for rare liver disease
Roche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
